Selective XPO1/CRM1 Inhibitor Verdinexor (KPT-335): The First and Only Oral Treatment Fully Approved by the U.S. FDA for Canine Lymphoma
Journal of Medicinal Chemistry · 17.11.2026
DOI: 10.1021/acs.jmedchem.6c03499 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 17.11.2026. Verfasst von Zonghui Ma und 7 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Central Public-interest Scientific Institution Basal Research Fund, Chinese Academy of Fishery Sciences.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Central Public-interest Scientific Institution Basal Research Fund, Chinese Academy of Fishery Sciences
Zitieren
APA
Ma, Z., Song, Z., Zhang, J., Liu, K., Han, X., Roque, J. L. V., Vega, A. L., & Zhou, W. (2026). Selective XPO1/CRM1 Inhibitor Verdinexor (KPT-335): The First and Only Oral Treatment Fully Approved by the U.S. FDA for Canine Lymphoma. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c03499
Vancouver
Ma Z, Song Z, Zhang J, Liu K, Han X, Roque JLV, et al. Selective XPO1/CRM1 Inhibitor Verdinexor (KPT-335): The First and Only Oral Treatment Fully Approved by the U.S. FDA for Canine Lymphoma. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c03499
BibTeX
@article{Ma2026,
author = {Ma, Zonghui and Song, Zihao and Zhang, Jiakun and Liu, Kaidi and Han, Xiangan and Roque, José Luis Vaca and Vega, Ariel Loza and Zhou, Wen},
title = {Selective XPO1/CRM1 Inhibitor Verdinexor (KPT-335): The First and Only Oral Treatment Fully Approved by the U.S. FDA for Canine Lymphoma},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c03499}
}
EUVIMED